To determine whether granulocyte-colony stimulating factor and erythropoietin are effective in the therapy of neutropenia and anaemia related to human immunodeficiency virus (HIV) infection and to anti-retroviral agents, we recruited 11 HIV-infected children (mean age 4 years 10 months). All the children were given granulocyte-colony stimulating factor at a dosage of 5 μg/kg twice or three times a week while erythropoietin was administered additionally to three patients at a dosage of 50 U/kg twice a week. Both agents were administered subcutaneously for at least 4 months. Leukocyte and neutrophil counts significantly increased during the treatment (after 1 month, P = 0.003 and P = 0.009, respectively). Erythropoietin prevented blood transfusions and increased haemoglobin levels in the three children treated. No side-effects were recorded during the administration of either agent. Granulocyte-colony stimulating factor and erythropoietin appear to be safe and useful agents in the management of HIV-infected children

Granulocyte-colony stimulating factor and erythropoietin therapy in children with human immunodeficiency virus infection / Zuccotti, Gv; Plebani, A; Biasucci, G; Clerici-Schoeller, M; Banderali, G; Decarlis, S; Startari, R; Riva, E. - In: JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. - ISSN 0300-0605. - 24:(1996), pp. 115-121. [10.1177/030006059602400115]

Granulocyte-colony stimulating factor and erythropoietin therapy in children with human immunodeficiency virus infection

Biasucci G;
1996-01-01

Abstract

To determine whether granulocyte-colony stimulating factor and erythropoietin are effective in the therapy of neutropenia and anaemia related to human immunodeficiency virus (HIV) infection and to anti-retroviral agents, we recruited 11 HIV-infected children (mean age 4 years 10 months). All the children were given granulocyte-colony stimulating factor at a dosage of 5 μg/kg twice or three times a week while erythropoietin was administered additionally to three patients at a dosage of 50 U/kg twice a week. Both agents were administered subcutaneously for at least 4 months. Leukocyte and neutrophil counts significantly increased during the treatment (after 1 month, P = 0.003 and P = 0.009, respectively). Erythropoietin prevented blood transfusions and increased haemoglobin levels in the three children treated. No side-effects were recorded during the administration of either agent. Granulocyte-colony stimulating factor and erythropoietin appear to be safe and useful agents in the management of HIV-infected children
1996
Granulocyte-colony stimulating factor and erythropoietin therapy in children with human immunodeficiency virus infection / Zuccotti, Gv; Plebani, A; Biasucci, G; Clerici-Schoeller, M; Banderali, G; Decarlis, S; Startari, R; Riva, E. - In: JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. - ISSN 0300-0605. - 24:(1996), pp. 115-121. [10.1177/030006059602400115]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2930901
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 2
social impact